Replimune Group, Inc. (NASDAQ:REPL) to Post Q2 2025 Earnings of ($0.77) Per Share, Leerink Partnrs Forecasts

Replimune Group, Inc. (NASDAQ:REPLFree Report) – Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of Replimune Group in a report released on Friday, February 9th. Leerink Partnrs analyst J. Chang expects that the company will post earnings of ($0.77) per share for the quarter. The consensus estimate for Replimune Group’s current full-year earnings is ($3.55) per share. Leerink Partnrs also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.69) EPS.

Other research analysts have also issued reports about the stock. Wedbush restated an “outperform” rating and set a $52.00 price target on shares of Replimune Group in a research report on Wednesday, November 8th. HC Wainwright reduced their price objective on shares of Replimune Group from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, November 13th. Finally, Barclays cut their price target on Replimune Group from $50.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 6th.

Get Our Latest Research Report on REPL

Replimune Group Stock Up 2.4 %

REPL opened at $7.95 on Monday. The company has a 50 day moving average of $8.05 and a 200 day moving average of $13.32. Replimune Group has a 12 month low of $5.89 and a 12 month high of $25.34. The company has a market cap of $488.05 million, a PE ratio of -2.52 and a beta of 1.22. The company has a current ratio of 12.40, a quick ratio of 12.40 and a debt-to-equity ratio of 0.16.

Replimune Group (NASDAQ:REPLGet Free Report) last issued its quarterly earnings results on Thursday, February 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.12.

Institutional Trading of Replimune Group

A number of large investors have recently made changes to their positions in the stock. Hsbc Holdings PLC lifted its stake in shares of Replimune Group by 19.3% during the 4th quarter. Hsbc Holdings PLC now owns 23,532 shares of the company’s stock worth $195,000 after purchasing an additional 3,814 shares during the last quarter. Quest Partners LLC acquired a new position in Replimune Group during the fourth quarter valued at $76,000. Clearbridge Investments LLC acquired a new stake in Replimune Group during the 4th quarter worth about $2,282,000. UBS Group AG raised its position in Replimune Group by 267.7% during the fourth quarter. UBS Group AG now owns 220,427 shares of the company’s stock valued at $1,858,000 after acquiring an additional 160,484 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Replimune Group by 517.9% in the fourth quarter. BNP Paribas Financial Markets now owns 196,251 shares of the company’s stock valued at $1,654,000 after acquiring an additional 164,490 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Replimune Group

In other news, insider Konstantinos Xynos sold 7,313 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $10.92, for a total transaction of $79,857.96. Following the transaction, the insider now owns 112,714 shares of the company’s stock, valued at approximately $1,230,836.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 20.60% of the company’s stock.

About Replimune Group

(Get Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Read More

Earnings History and Estimates for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with's FREE daily email newsletter.